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TO THE EDITOR
Vemurafenib, a BRAF-targeted therapy,
has revolutionized the treatment of
metastatic melanoma by showing highly
significant clinical objective responses
compared with those obtained hitherto
with standard treatments in patients
presenting a BRAFV600 mutation in
their tumor in a phase III clinical trial
(Flaherty et al., 2010; Chapman et al.,
2011). These mutations are found in
B50% of melanoma patients (Davies
et al., 2002). Since then, this new drug
has been approved in many countries
for the treatment of patients with unrese-
ctable or metastatic melanoma with a
BRAF mutation (BRAFV600E in the United
States, BRAFV600 in Europe). Therefore,
daily practice requires BRAF mutation
testing of patients’ tumors, in order to
start BRAF-inhibitor therapy. However,
it is not known whether primary
tumors and metastatic lesions can be
tested equivalently for BRAF mutations,
and there is no recommendation
on the number of samples to be tested
(Gonzalez et al., 2013). Further-
more, little data are available on
multiple melanoma sample testing in
the same patient.
We retrospectively determined the
BRAF mutation status of all samples
from consecutive inpatients with mela-
noma available in our unit between
January 2011 and June 2012. DNA
was extracted from paraffin-embedded
tumor blocks after highlighting tumor
areas by a pathologist and macrodissec-
tion. Detection of the most frequent
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Figure 1. Patients with several melanoma samples tested. (a) Patients with two samples tested for BRAF
mutation (n¼ 59), (b) patients with three samples tested for BRAF mutation (n¼15).
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BRAF mutations was performed by
allele-specific amplification as pre-
viously described (Jarry et al., 2004)
and completed in all cases by con-
ventional Sanger DNA sequencing. The
allele-specific amplification sensitivity
was 5% for the BRAFV600E mutation,
which is equivalent to the sensitivity of
approved commercially available tests
(for instance, Cobas BRAFV600 in the
United States, Canada, and Europe and
Therascreen BRAF RGQ in Europe).
A total of 367 melanoma samples
from 278 patients were tested.
A BRAF mutation was found in 152
samples (41.4%) corresponding to 114
patients (41%). Seven samples were
BRAFV600K mutated (2%) and two
were BRAFV600R (0.6%), all the others
being BRAFV600E. Among the whole
population, 74 patients (27%) had
several samples tested (59 patients with
two samples and 15 with three samples,
Figure 1). Ten out of these 74 patients
(13.5%) with multiple tests had BRAF
status discordant results (Table 1). False-
negative results can be generated when
using methods with a low analytical
sensitivity (Schoenewolf et al., 2012;
Lade-Keller et al., 2013). Therefore, we
analyzed these samples by using a third
approach (Therascreen BRAF RGQ assay,
Qiagen) that confirmed the results. Eight
out of these 10 patients had two samples
and two patients had three samples
tested. For two patients, the BRAF
status discordance was found between
the primary tumor and a metastasis. For
six patients, this discordance existed
between two distinct metastases. The
two patients with three samples
corresponded to three metastases. The
rate of discordance in BRAF status was
different according to the type of
samples tested: 8% (2/25) in patients
with a test performed on the primary
tumor and one metastasis, 18% (6/33) in
patients with a test performed on two
metastases, and 20% (2/10) in patients
with a test performed on three metastases.
Among the 10 patients with discor-
dant results, two patients (#1 and #7)
were treated with vemurafenib. For
patient #1, the two samples corre-
sponded to two cutaneous metastases,
the first one being BRAF wild type and
the second one, sampled 6.5 years later,
being BRAFV600E mutated. He experi-
enced a stabilization of the disease
for a long period (9 months) on both
metastases. For patient #7, the two first
samples (lymph node and cutaneous
metastases) were BRAFV600E mutated
and the liver analysis sampled 1 month
before starting vemurafenib was BRAF
wild type. This patient achieved a partial
response for 8 months, including, inter-
estingly, the BRAF wild-type liver
metastasis.
Our results demonstrate that BRAF
discordant status between the distinct
samples can be found in a significant
proportion of melanoma patients
(almost 14%). This proportion is vari-
able, depending on the type of samples
tested (from 8 to 20%), and the highest
rate of discordance was found when
three distinct metastases in the same
patient were tested. It is noteworthy that,
in our study, performing multiple BRAF
testing allowed to detect a BRAF
mutation in a second or a third sample
for five patients, who were previously
wild type (patients #1, 6, 8, 9, and 10).
In the absence of repeated testing, these
five patients would have been excluded
from the vemurafenib therapy. Conver-
sely, according to the therapeutic
response of patient #7, it seems unne-
cessary to test again a previous BRAF-
mutated patient. Indeed, even if the liver
metastasis was BRAF wild type, patient
#7 experienced a partial response with
vemurafenib therapy including on the
BRAF wild-type metastasis.
Two previous studies described the
existence of BRAF discordant tests for
the same patients, but the relation with
the response to vemurafenib was not
discussed. Colombino et al. (2012)
studied BRAF and NRAS statuses in
99 patients with paired samples of
primary melanomas and metastases.
They observed 84 patients (85%) with
Table 1. Discordant BRAF status in melanoma samples
Patient Weeks1 BRAF status Sample location Percentage of melanoma cells
1 0 Wt Cut met 450
1 337 V600E Cut met 450
2 0 V600E Cut met 450
2 304 Wt Cut met 450
3 0 Wt LN met 25–50
3 0 V600E Cut met 450
4 0 V600E LN met 80
4 22 Wt Cut met 450
4 37 Wt LN met 450
5 0 V600E Primary 450
5 18 Wt LN met 25–50
6 0 Wt Visc met 450
6 29 V600E Cut met o10
7 0 V600E LN met 450
7 39 V600E Cut met 450
7 47 Wt Visc met 450
8 0 Wt Primary 450
8 28 V600E LN met 450
9 0 Wt Cut met 450
9 3 V600E LN met 25–50
10 0 Wt LN met 450
10 6 V600E LN met 450
Abbreviations: Cut met, cutaneous metastasis; LN met, lymph node metastasis; Primary, primary
melanoma; Visc met, visceral metastasis; Wt, wild type.
1Time between the sampling of the different samples, W0 is the first melanoma sample screened for
BRAF mutation.
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consistent mutation patterns. In another
study using BRAF mutant–specific PCR
and conventional sequencing, the
authors included 18 patients with
matched primary melanoma and meta-
stasis and 19 patients with several
metastases, with discordance found in
eight (44%) and five (26%) patients,
respectively (Yancovitz et al., 2012).
These differences in the BRAF dis-
cordance rate among the studies may
be explained by the population, the
number of samples tested, or by
technical aspects. This inter-tumor
heterogeneity on BRAF status is
probably linked to the existence of
different subclones in the primary
melanoma (Lin et al., 2011; Yancovitz
et al., 2012).
In conclusion, we highlight that the
absence of BRAFV600 mutation in one
melanoma tumor sample is not a
definitive result. In a BRAF wild-type
patient, it is essential to test again
other samples during the evolution of
the disease or at the same time on
different tumor lesions (synchronous
or metachronous metastases). BRAF
inhibitors being actually one of the
most effective therapies in metastatic
melanoma, a patient should not be
excluded from vemurafenib therapy
on the basis of a single BRAF wild-
type result.
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TO THE EDITOR
Malignant melanoma is a highly aggres-
sive form of skin cancer that can be
difficult to manage once metastasis
has occurred. Tumor necrosis factor-a
(TNF-a) is a cytokine that influences
the tumor microenvironment, activates
tumor inflammation, and induces cell
death (Balkwill, 2009). TNF-a induces
the signal-transduction pathways asso-
ciated with cell survival through NF-kB
or caspase 8. Melanoma cells can pro-
duce TNF-a (Landsberg et al., 2012);
however, its expression is heterogenous
and the regulation of tumor cell TNF-a
production is poorly understood.
Epigenetic deregulation has an impor-
tant role in aberrant gene expression
and melanoma progression (Tanemura
et al., 2009). Several tumor-related
genes are consistently aberrantly hyper-
methylated during melanoma progres-
sion (Tanemura et al., 2009; Greenberg
et al., 2012; Hoshimoto et al., 2012).
Similarly, histone modification has alsoAccepted article preview online 13 November 2013; published online 12 December 2013
Abbreviations: ChIP, chromatin immunoprecipitation; DZNep, 3-deazaneplanocin A; EZH2, enhancer of
zeste homolog 2; MSP, methylation-specific PCR assay; PRC2, polycomb-repressive complex 2; PI,
propidium iodide; qPCR, quantitative PCR; qRT-PCR, quantitative real-time reverse-transcriptase–PCR; RT-
PCR, reverse transcriptase–PCR; SUZ12, suppressor of zeste 12 homolog (Drosophila); TNF-a, tumor
necrosis factor-a; TSA, trichostatin A
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